Operates as an anti-infective drug development company
Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections.
Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections.
The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
|Vote ||Quantity||Float||Company-owned shares||Total Float
|East Hill Management Co. LLC ||3,068,358||
|Krensavage Asset Management LLC ||2,836,326||
|SC Fund Management LLC ||2,429,864||
|Armistice Capital LLC ||1,378,463||
|Renaissance Technologies LLC ||1,193,485||
|The Vanguard Group, Inc. ||990,809||
|Fidelity Management & Research Co. ||980,683||
|BlackRock Fund Advisors ||476,751||
|Landon Thomas Clay ||413,259||
|Gabelli & Co. Investment Advisers, Inc. ||224,477||
|Company contact information|
Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Alpharetta, GA 30009
Phone : +1.678.221.3343
Web : www.aviragen.com
Sector Bio Therapeutic Drugs
Connections : Biota Pharmaceuticals Inc
© 2017 People , Fundamentals and Ownership